Summary
Eli Lilly and Company's 2012 10-K filing reveals a challenging year marked by a 7% decrease in worldwide revenue to $22.6 billion, primarily driven by the significant sales decline of Zyprexa following patent expirations in major markets. Net income and earnings per share also saw a decrease. Despite the revenue headwinds, the company highlighted growth in key products like Cymbalta, Forteo, Effient, and Alimta, alongside a strong performance in its animal health division (Elanco). Lilly's extensive research and development pipeline remains a significant focus, with numerous compounds in various stages of clinical trials, including promising candidates for diabetes, cancer, and Alzheimer's disease. The company also announced significant progress on dulaglutide and empagliflozin for diabetes treatment. Looking ahead, Lilly faces continued pressure from patent expiries, particularly for Cymbalta in late 2013, which is expected to materially impact future results. The company is strategically focusing on its patent-protected products, emerging markets, and animal health business to offset these challenges. Additionally, the filing details ongoing litigation, regulatory scrutiny, and the impact of healthcare reforms, all of which present ongoing risks and require careful management.
Financial Highlights
53 data points| Revenue | $22.60B |
| Cost of Revenue | $4.80B |
| Gross Profit | $17.81B |
| R&D Expenses | $5.28B |
| SG&A Expenses | $7.51B |
| Interest Expense | $177.80M |
| Net Income | $4.09B |
| EPS (Basic) | $3.67 |
| EPS (Diluted) | $3.66 |
| Shares Outstanding (Basic) | 1.11B |
| Shares Outstanding (Diluted) | 1.12B |
Key Highlights
- 1Worldwide revenue declined 7% to $22.6 billion in 2012, largely due to Zyprexa's patent expiration.
- 2Net income decreased by 6% to $4.09 billion, with EPS falling to $3.66.
- 3Cymbalta, Forteo, Effient, and Alimta showed revenue growth, partially offsetting declines in other products.
- 4Elanco Animal Health division demonstrated strong growth, with sales up 21% in the U.S. and 12% internationally.
- 5The company highlighted its robust late-stage pipeline, including positive developments for diabetes treatments dulaglutide and empagliflozin.
- 6Lilly anticipates significant revenue decline for Cymbalta following its U.S. patent expiration in December 2013.
- 7The company continues to invest heavily in R&D, with $5.28 billion spent in 2012, focusing on key therapeutic areas including diabetes, oncology, and neuroscience.